Skip to content

Life Sciences

Choosing the worst-case product for cleaning validation

  • Life Sciences
  • 1 min read

Validating the cleaning ten times for the ten products on one line is rarely needed, provided one of them is truly the worst case.

The 2015 text of EU GMP Annex 15 allows the approach with a condition attached: a scientific rationale should be provided for the selection of the worst-case product. The criteria it names may include solubility, cleanability, toxicity and potency.

These criteria rarely point at the same product: the least soluble active need not be the most toxic one. So the rationale ends up as a table, one row per product, with these columns filled in:

  1. The health-based exposure limit (PDE) from the toxicological evaluation. The lowest one sets the tightest residue limit.
  2. Solubility of the active in the cleaning medium actually used.
  3. Cleanability in practice: what operators and past swab results say is hard to remove.
  4. Strength and batch size, which fix how much active is on the surface to begin with.

When two products split the columns, a common answer is to validate on the one hardest to clean, against the lowest residue limit calculated in the group. APIC's cleaning validation guidance works an example on those lines.

Annex 15 also asks for the impact of new products to be assessed. The table therefore carries a date. A new product on the line reopens it; the old validation is not assumed to cover it.

Industries

Related

More on this subject

Comparative method transfer: where the criteria come from

In a comparative method transfer, two laboratories test the same lots. EU GMP Chapter 6 says the transfer should be described in a detailed protocol, with acceptance criteria based upon the current validation study of the method. Agree the criteria before execution, train the analysts, compare the results against the criteria and investigate deviations before closure.

InsightRead

Concurrent validation is the exceptional route

EU GMP Annex 15 (2015) accepts concurrent validation in exceptional circumstances, where there is a strong benefit-risk ratio for the patient. The decision must be justified, documented in the validation master plan and approved by authorised personnel. A project that is running late does not meet that test.

InsightRead

Cpk 1.33: a convention, and what the GMP texts say instead

A Cpk of 1.33 puts the nearer specification limit 4 standard deviations from the process mean. It is a statistical convention: EU GMP Annex 15 (2015 text) and the FDA guidance of 2011 recommend statistical tools and name no index. With 10 batches the confidence interval is wide, so report the batch count and the interval.

InsightRead